Entecavir (Baraclude®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015000597
English
Authors' recommendations:
Entecavir (Baraclude®) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B virus (HBV) infection in nucleoside naive paediatric patients from 2 to < 18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum alanine aminotransferase (ALT) levels, or histological evidence of moderate to severe inflammation and/or fibrosis.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2546
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Practice Guidelines as Topic
- Quality of Life
- Randomized Controlled Trials as Topic
- Russia
- Treatment Outcome
- Antiviral Agents
- Guanine
- Hepatitis B, Chronic
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.